Atlas Trials

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Clinical trial NCT03158688 · COMPLETED

Trial details

NCT number
NCT03158688
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Start date
2017-06-13
Primary completion
2019-07-14
Enrollment
466

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.